FDA approves acalabrutinib plus chemoimmunotherapy in previously untreated MCL
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, has been approved in the United States in combination with bendamustine and rituximab for the treatment
Lymphoma
Mantle Cell Lymphoma
News
Leukemia
Chronic Myeloid Leukemia
IND approved in Korea for CML treatment KF1601
An Investigational New Drug (IND) application for KF1601, a chronic myeloid leukemia (CML) treatment was submitted to and approved by the Korea Ministry
Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
FDA grants fast track designation to LYT-200 in AML
The US Food and Drug Administration (FDA) has granted fast track designation to LYT-200 for the treatment of acute myeloid leukemia (AML). LYT-200
Cellular Therapy
Lymphoma
CAR-NK cell therapy FT596 ‘well tolerated’ in phase 1 trial
FT596, a CD19-directed chimeric antigen receptor (CAR) natural killer (NK) cell therapy, was well tolerated in patients with relapsed or refractory B-cell lymphoma
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
News
Video Interviews
Refining progression criteria in relapsed myeloma
Jean-Sébastien Claveau, MD, of Maisonneuve-Rosemont Hospital at the University of Montreal, spoke with SOHO Insider at the 66th American Society of Hematology Annual
Cellular Therapy
Multiple Myeloma
News
Do older patients with myeloma respond as well to ide-cel as younger patients?
“[T]hese findings provide reassurance that older adults treated with ide-cel, including frail patients, experience comparable efficacy to younger patients,” the authors wrote.
Multiple Myeloma
News
Society Updates
Message from Editor-in-Chief Dr. Lonial: Advancing care amid uncertainty
May you live in interesting times…. You may have encountered this adage at some point in your life, though its origins are difficult
Myeloproliferative Neoplasms
Primary Myelofibrosis
Do driver mutations influence treatment outcomes in myelofibrosis?
The absence of cancer-related mutations 30 days after a transplant in patients with myelofibrosis might be more effective in measuring treatment response than
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
Researchers call for ‘evidence-based’ driving restrictions for patients treated with CAR-T therapy
Driving restrictions for blood cancer patients undergoing chimeric antigen receptor (CAR)-T cell therapy may need reconsideration.
Leukemia
Myelodysplastic Syndromes
FDA approves imatinib oral solution to treat leukemia, other cancers
The US Food and Drug Administration (FDA) has approved imatinib (Imkeldi) oral solution to treat leukemia and other cancers. Imatinib is an advanced